CELZ vs VRTX: Which Stock is Better?
Side-by-side comparison of Creative Medical Technology Holdings Inc and Vertex Pharmaceuticals Inc in 2026
CELZ
Creative Medical Technology Holdings Inc
$2.47
VRTX
Vertex Pharmaceuticals Inc
$441.20
Key Metrics Comparison
| Metric | CELZ | VRTX | Winner |
|---|---|---|---|
| Market Cap | $8.61M | $110.81B | VRTX |
| P/E Ratio | N/A | 28.42 | VRTX |
| EPS (TTM) | $N/A | $15.33 | VRTX |
| Revenue Growth | 0.0% | 0.1% | VRTX |
| Gross Margin | 63.4% | 53.7% | CELZ |
Analyze CELZ
Full quant analysis
Analyze VRTX
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is CELZ or VRTX a better investment?
Comparing CELZ and VRTX: Creative Medical Technology Holdings Inc has a market cap of $8.61M while Vertex Pharmaceuticals Inc has $110.81B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between CELZ and VRTX?
CELZ (Creative Medical Technology Holdings Inc) and VRTX (Vertex Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: CELZ or VRTX?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: CELZ or VRTX?
VRTX has higher revenue growth at 0.1% vs 0.0% for CELZ.
Which company is more profitable: CELZ or VRTX?
Creative Medical Technology Holdings Inc (CELZ) has higher gross margins at 63.4% compared to 53.7% for VRTX.
Which is the larger company: CELZ or VRTX?
Vertex Pharmaceuticals Inc (VRTX) is larger with a market cap of $110.81B compared to $8.61M for CELZ.
Should I buy CELZ or VRTX in 2026?
Both CELZ and VRTX have investment merit. CELZ trades at $2.47 while VRTX trades at $441.20. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between CELZ and VRTX stock?
Key differences: Market Cap ($8.61M vs $110.81B), P/E Ratio (N/A vs 28.4x), Revenue Growth (0.0% vs 0.1%), Gross Margin (63.4% vs 53.7%).